BAUSCH HEALTH COMPANIES INC.
BHCLoading price...
Overview
Previous Close4.68
Open4.97
Ask6.00
Bid5.92
Day's Range4.97 - 6.06
52 Week Range4.33 - 8.69
PE Ratio(TTM)--
Market Cap2.25B
Volume18.17M
Avg. Volume2.23M
12 Months Earnings-1.21B
12 Months Revenue10.53B
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 10.53B | 10.27B | 9.86B | 9.62B | 8.76B | 8.12B |
| Cost of Revenue | 3.05B | 3.01B | 2.89B | 2.78B | 2.56B | 2.36B |
| Gross Profit | 7.48B | 7.25B | 6.97B | 6.84B | 6.20B | 5.76B |
| Operating Expenses | 5.07B | 5.07B | 5.09B | 4.99B | 4.60B | 4.37B |
| Profit after Tax (Net Income) | -1.21B | 157.00M | 98.00M | -46.00M | -592.00M | -225.00M |
Company Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ Location: Laval, Canada
Website: https://www.bauschhealth.com
CEO & Director: Mr. Thomas J. Appio
Employees: 20,300
About Company:
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.